Diagnostic and prognostic utility of urinary creatine riboside for early stage non-small cell lung cancer

Authors

• Y Kanke
• T Oike
• A Parker
• M Haznadar
• GT Pauly
• KW Krausz
• AI Robles
• ED Bowman
• FJ Gonzalez
• CC Harris

Abstract

Introduction: There are no validated molecular methods that prospectively identify patients with surgically treated early stage non-small cell lung cancer (NSCLC) at high risk for recurrence. We previously found that urinary creatine riboside (CR), N-acetylneuraminic acid (NANA), cortisol sulfate (CS) and as-yet-unidentified metabolite 561+ have diagnostic and prognostic significance for lung cancer. Here, we investigated the usefulness of the urinary metabolites for clinical management after surgery in early stage NSCLC patients. Methods: CR, NANA, CS and 561+ in urine from 32 surgically treated stage I–II NSCLC patients collected at multiple pre- and post-surgery time points were quantitated using ultraperformance liquid chromatography coupled to tandem mass spectrometry. Trend in metabolite levels over clinical course was examined by Jonckheere–Terpstra test. Association of metabolite levels with survival was examined by Log-rank test for Kaplan–Meier survival curves. Results: In non-recurrent patients, CR and NANA showed significant decreasing trend after surgery over 2 years (P=0.048 and

Scientific Focus Area: Cancer Biology

This page was last updated on Friday, March 26, 2021